Monday, December 23, 2024
HomeIndustriesBiotechnology

Biotechnology

Antengene Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate ATG-017 in Combination with Opdiv (nivolumab) in Advanced Solid Tumors

Antengene Corporation Limited, a leading innovative, global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer and other life-threatening...

IASO Biotherapeutics and Innovent Biologics Announced Updated Clinical Data of BCMA CAR-T Therapy in Oral Presentation at 2021 ASH Annual Meeting

IASO Biotherapeutics, a clinical-stage biopharmaceutical company focused on discovering, developing, and manufacturing innovative medicines and Innovent Biologics, Inc., a world-class biopharmaceutical company that develops,...

PharmaMar and Jazz Pharmaceuticals Announce Initiation of Confirmatory Phase 3 Clinical Trial of Zepzelca® (lurbinectedin) for the Treatment of Patients with Relapsed Small Cell...

PharmaMar and partner Jazz Pharmaceuticals plc announced the initiation of a confirmatory Phase 3 clinical trial, LAGOON, evaluating Zepzelca® (lurbinectedin) for the treatment of...

Rejuveron Increases to Near-majority Stake in Endogena Through Funding $20m to Progress Treatments for Degenerative Diseases of the Eye

Rejuveron Life Sciences AG, a Zürich-based biotechnology company developing technologies for healthy aging, announced that it has strengthened its support to a near-majority holding...

Biocytogen/Eucure Biopharma Announce the Completion of First Patient Dosing for Phase II Clinical Trial of YH003 in Australia

Eucure Biopharma, a wholly owned subsidiary of Biocytogen, announced the first patient dosing for a phase II clinical trial of YH003 (anti-CD40 monoclonal antibody,...
0FansLike
0FollowersFollow
spot_img

Hot Topics